Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
13.39
+0.59 (4.61%)
Dec 3, 2025, 4:00 PM EST - Market closed
Alto Neuroscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
76
Market Cap
415.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 210.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionANRO News
- 5 days ago - Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026 - Seeking Alpha
- 21 days ago - Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 5 weeks ago - Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Alto Neuroscience Announces $50 Million Private Placement Financing - Business Wire
- 6 weeks ago - Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting - Business Wire
- 2 months ago - Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders - GlobeNewsWire
- 2 months ago - Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders - GlobeNewsWire
- 2 months ago - Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia - Business Wire